495 related articles for article (PubMed ID: 16344514)
21. Successful treatment of acute autoimmune limbic encephalitis with negative VGKC and NMDAR antibodies.
Modoni A; Masciullo M; Spinelli P; Marra C; Tartaglione T; Andreetta F; Tonali P; Silvestri G
Cogn Behav Neurol; 2009 Mar; 22(1):63-6. PubMed ID: 19372772
[TBL] [Abstract][Full Text] [Related]
22. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association.
Saiz A; Blanco Y; Sabater L; González F; Bataller L; Casamitjana R; Ramió-Torrentà L; Graus F
Brain; 2008 Oct; 131(Pt 10):2553-63. PubMed ID: 18687732
[TBL] [Abstract][Full Text] [Related]
23. VGKC complex antibodies in epilepsy: diagnostic yield and therapeutic implications.
Lilleker JB; Jones MS; Mohanraj R
Seizure; 2013 Nov; 22(9):776-9. PubMed ID: 23838087
[TBL] [Abstract][Full Text] [Related]
24. Clinical spectrum of voltage-gated potassium channel autoimmunity.
Tan KM; Lennon VA; Klein CJ; Boeve BF; Pittock SJ
Neurology; 2008 May; 70(20):1883-90. PubMed ID: 18474843
[TBL] [Abstract][Full Text] [Related]
25. Glutamic acid decarboxylase autoantibodies and neurological disorders.
Vianello M; Tavolato B; Giometto B
Neurol Sci; 2002 Oct; 23(4):145-51. PubMed ID: 12536283
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy.
Brenner T; Sills GJ; Hart Y; Howell S; Waters P; Brodie MJ; Vincent A; Lang B
Epilepsia; 2013 Jun; 54(6):1028-35. PubMed ID: 23464826
[TBL] [Abstract][Full Text] [Related]
27. New autoantibody mediated disorders of the central nervous system.
Lang B; Dale RC; Vincent A
Curr Opin Neurol; 2003 Jun; 16(3):351-7. PubMed ID: 12858073
[TBL] [Abstract][Full Text] [Related]
28. [A spectrum of neurological diseases with anti-VGKC antibody].
Arimura K; Watanabe O; Nagado T
Rinsho Shinkeigaku; 2007 Nov; 47(11):845-7. PubMed ID: 18210814
[TBL] [Abstract][Full Text] [Related]
29. Neuropsychological course of voltage-gated potassium channel and glutamic acid decarboxylase antibody related limbic encephalitis.
Frisch C; Malter MP; Elger CE; Helmstaedter C
Eur J Neurol; 2013 Sep; 20(9):1297-304. PubMed ID: 23678940
[TBL] [Abstract][Full Text] [Related]
30. Sequential antibodies to potassium channels and glutamic acid decarboxylase in neuromyotonia.
Antozzi C; Frassoni C; Vincent A; Regondi MC; Andreetta F; Bernasconi P; Ciano C; Chang T; Cornelio F; Spreafico R; Mantegazza R
Neurology; 2005 Apr; 64(7):1290-3. PubMed ID: 15824370
[TBL] [Abstract][Full Text] [Related]
31. Autoantibodies against voltage-gated potassium channel and glutamic acid decarboxylase in psychosis: A systematic review, meta-analysis, and case series.
Grain R; Lally J; Stubbs B; Malik S; LeMince A; Nicholson TR; Murray RM; Gaughran F
Psychiatry Clin Neurosci; 2017 Oct; 71(10):678-689. PubMed ID: 28573688
[TBL] [Abstract][Full Text] [Related]
32. Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies.
Matà S; Muscas GC; Naldi I; Rosati E; Paladini S; Cruciatti B; Bisulli F; Paganini M; Mazzi G; Sorbi S; Tinuper P
J Neuroimmunol; 2008 Aug; 199(1-2):155-9. PubMed ID: 18586329
[TBL] [Abstract][Full Text] [Related]
33. Antiglutamic acid decarboxylase antibodies in children with encephalitis and status epilepticus.
Lin JJ; Lin KL; Hsia SH; Wang HS; Chou IJ; Lin YT;
Pediatr Neurol; 2012 Oct; 47(4):252-8. PubMed ID: 22964438
[TBL] [Abstract][Full Text] [Related]
34. Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability.
Vernino S; Lennon VA
Muscle Nerve; 2002 Nov; 26(5):702-7. PubMed ID: 12402293
[TBL] [Abstract][Full Text] [Related]
35. Autoimmune epilepsy: distinct subpopulations of epilepsy patients harbor serum autoantibodies to either glutamate/AMPA receptor GluR3, glutamate/NMDA receptor subunit NR2A or double-stranded DNA.
Ganor Y; Goldberg-Stern H; Lerman-Sagie T; Teichberg VI; Levite M
Epilepsy Res; 2005 Jun; 65(1-2):11-22. PubMed ID: 15978777
[TBL] [Abstract][Full Text] [Related]
36. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus.
Solimena M; Folli F; Denis-Donini S; Comi GC; Pozza G; De Camilli P; Vicari AM
N Engl J Med; 1988 Apr; 318(16):1012-20. PubMed ID: 3281011
[TBL] [Abstract][Full Text] [Related]
37. Routine diagnostics for neural antibodies, clinical correlates, treatment and functional outcome.
Bien CG; Bien CI; Dogan Onugoren M; De Simoni D; Eigler V; Haensch CA; Holtkamp M; Ismail FS; Kurthen M; Melzer N; Mayer K; von Podewils F; Rauschka H; Rossetti AO; Schäbitz WR; Simova O; Witt K; Höftberger R; May TW
J Neurol; 2020 Jul; 267(7):2101-2114. PubMed ID: 32246252
[TBL] [Abstract][Full Text] [Related]
38. Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity.
Rakocevic G; Raju R; Dalakas MC
Arch Neurol; 2004 Jun; 61(6):902-4. PubMed ID: 15210528
[TBL] [Abstract][Full Text] [Related]
39. Anticardiolipin, glutamic acid decarboxylase, and antinuclear antibodies in epileptic patients.
Verrotti A; Greco R; Altobelli E; Latini G; Morgese G; Chiarelli F
Clin Exp Med; 2003 May; 3(1):32-6. PubMed ID: 12748877
[TBL] [Abstract][Full Text] [Related]
40. Voltage-gated potassium channel (K(v) 1) autoantibodies in patients with chagasic gut dysmotility and distribution of K(v) 1 channels in human enteric neuromusculature (autoantibodies in GI dysmotility).
Hubball AW; Lang B; Souza MA; Curran OD; Martin JE; Knowles CH
Neurogastroenterol Motil; 2012 Aug; 24(8):719-28, e344. PubMed ID: 22591165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
